Fragmented Care in Pancreatic Cancer Doesn’t Impact Survival

A study on localized pancreatic cancer investigated whether fragmented care, where patients receive systemic therapy at a different facility than their surgery, affected survival. Among over 11,000 patients, those treated in Commission on Cancer accredited facilities were more likely to receive neoadjuvant therapy, but overall survival didn’t significantly differ compared to non-fragmented care or fragmented care in non-accredited facilities. The study suggests that the accreditation status of the treatment facility doesn’t substantially impact the survival of patients with localized pancreatic cancer.